日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo

一种新型 EGFR 抑制剂可作为缺氧激活前药系统的有效工具,并在体外和体内与 VEGFR 抑制剂发挥强大的协同作用

Monika Caban, Bettina Koblmueller, Diana Groza, Hemma H Schueffl, Alessio Terenzi, Alexander Tolios, Thomas Mohr, Marlene Mathuber, Kushtrim Kryeziu, Carola Jaunecker, Christine Pirker, Bernhard K Keppler, Walter Berger, Christian R Kowol, Petra Heffeter

Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance

开发硫脲衍生物以克服 COTI-2 耐药性

Vivien Pósa, Alessia Stefanelli, Julia H Bormio Nunes, Sonja Hager, Marlene Mathuber, Nóra V May, Walter Berger, Bernhard K Keppler, Christian R Kowol, Éva A Enyedy, Petra Heffeter

Development of a cobalt(iii)-based ponatinib prodrug system

基于钴(iii)的普纳替尼前药系统的开发

Marlene Mathuber, Michael Gutmann, Mery La Franca, Petra Vician, Anna Laemmerer, Patrick Moser, Bernhard K Keppler, Walter Berger, Christian R Kowol

Liposomal formulations of anticancer copper(II) thiosemicarbazone complexes

抗癌铜(II)缩氨基硫脲复合物的脂质体制剂

Marlene Mathuber, Sonja Hager, Bernhard K Keppler, Petra Heffeter, Christian R Kowol

Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux

癌细胞对临床研究的缩氨基硫脲 COTI-2 的耐药性是基于细胞内铜复合物谷胱甘肽加合物的形成和 ABCC1 介导的流出

Julia H Bormio Nunes, Sonja Hager, Marlene Mathuber, Vivien Pósa, Alexander Roller, Éva A Enyedy, Alessia Stefanelli, Walter Berger, Bernhard K Keppler, Petra Heffeter, Christian R Kowol

Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs

提高EGFR抑制剂钴(III)前药的稳定性

Marlene Mathuber, Hemma Schueffl, Orsolya Dömötör, Claudia Karnthaler, Éva A Enyedy, Petra Heffeter, Bernhard K Keppler, Christian R Kowol